Abstract: Peptides able to inhibit or activate the translocation or function of ?PKC are identified. Administration of the peptides for protection or enhancement of cell damage due to ischemia is described. Therapeutic methods to reduce damage to cells or to enhance damage to cells due to ischemia are also described, as well as methods for screening test compounds for ?PKC-selective agonists and antagonists.

Abstract: Small molecule polycationic agents are used to modulate or interrupt biological processes by binding to oligosaccharide-based biomolecules. Compounds that inhibit nitric oxide, TNF? or other immunomodulators are provided and are useful for treating immunological disease and disease of an infectious disorder.

Abstract: Computation-saving techniques and stability-adding techniques provide for fast, accurate reconstructions of a time series of images involving large-scale 3D problems, such as real-time image recovery in an optical tomography imaging system. A system equation for a target medium (116) such as tissue is solved using a Normalized Difference Method (NDM) (250). Because of the inherent stability of the NDM solutions, a weight matrix (W) of the system equation can be provided for a given point in a time series (220), then reused without recalculation at subsequent points. Further savings are achieved by decomposing W using singular value decomposition or direct matrix decomposition, transforming it to reduce its dimensions, and/or scaling it to achieve a more stable numerical solution. Values of measured energy (112) emerging from the target medium are back-substituted into the system equation for the different points to obtain the target medium properties.

Abstract: The invention relates to a novel protease, called SENP1, which is active against sentrin-modified proteins in vivo. The invention more specifically relates to the genomic and amino acid sequences for SENP1, compositions related to and based on these sequences, and methods of using these sequences and compositions.

Abstract: A method of controlling the activity of a biologically active compound. The method concerns an oligonucleotide-based compound, comprising a hairpin-forming oligonucleotide, an effector moiety physically associated with the oligonucleotide, where the effector moiety possesses a biological activity, and a regulating moiety physically associated with the oligonucleotide, where the regulating moiety controls the biological activity of the effector moiety by interacting with the effector moiety. The oligonucleotide can assume a hairpin configuration, where the effector and regulating moieties interact, or an open configuration, where the effector and regulating moieties fail to interact. Depending on the nature of the effector and regulating moieties, either configuration can result in the expression of the biological activity of the effector moiety.

Abstract: The present invention provides chemokine receptor antibodies that selectively bind to an activated form of the receptor but not to a non activated form of the receptor. In particular, the current invention provides phospho specific chemokine receptor antibodies. The antibodies can be used in several diagnostic, screening and purification methods.

Abstract: The present invention provides compounds and methods of administering compounds to a subject that can reduce ?APP production and that is not toxic in a wide range of dosages. The present invention also provides non-carbamate compounds and methods of administering such compounds to a subject that can reduce ?APP production and that is not toxic in a wide range of dosages. It has been discovered that either the racemic or enantiomerically pure non-carbamate compounds can be used to decrease ?APP production.

Abstract: The invention provides adenovirus and retrovirus vectors useful to prepare influenza virus. Also provided is a canine RNA polymerase I promoter and vectors having that promoter.

Abstract: The present invention relates to nucleic acid molecules comprising certain truncated forms of the human cytomegalovirus (CMV) immediate-early enhancer-promoter, either alone or operably linked to transgenes of interest, including those encoding partially-deleted CFTR proteins. This invention further relates to vectors comprising these nucleic acid molecules and host cells transformed by such vectors. The nucleic acid molecules, vectors and transformed host cells of the present invention are useful for treating a variety of genetic, metabolic and acquired diseases, including inter alia cystic fibrosis (CF) airway disease.